New-Onset Atrial Fibrillation After Exenatide Injection: Coincidence or Consequence?

Yamantuerk Y. Y., ESENBOĞA K., YILMAZ G. C., Baskovski E., CANDEMİR B., ŞAHİN M.

ENDOCRINOLOGY RESEARCH AND PRACTICE, sa.4, ss.241-244, 2023 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2023
  • Doi Numarası: 10.5152/erp.2023.23262
  • Dergi Adı: ENDOCRINOLOGY RESEARCH AND PRACTICE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.241-244
  • Ankara Üniversitesi Adresli: Evet

Özet

The glucagon-like peptide 1 receptor agonists, together with sodium-glucose cotransporter-2 inhibi-tors, are antidiabetic drugs known for their beneficial effects on the cardiovascular system; many phase 3 trials also support this conclusion. However, it can be thought that they may cause an increase in the risk of tachyarrhythmia due to the stimulation of their receptors in the sympathetic nervous system and sinoatrial cells. We report a case of a 71-year-old woman with no history of arrhythmia who presented with new-onset atrial fibrillation after an exenatide injection during clinical follow-up.